Top Markets
Coin of the day
Alimera Sciences, Inc. Alimera Sciences, Inc.

Alimera Sciences, Inc.

ALIM
株式のランク #26668
Alimera Sciences, Inc. is a pharmaceutical company focused on developing and... Alimera Sciences, Inc. is a pharmaceutical company focused on developing and commercializing ophthalmic treatments globally, including in the United States. Its primary offering, ILUVIEN, is an intravitreal implant used to manage diabetic macular edema (DME), a severe retinal disease in individuals with diabetes that can lead to profound vision loss and blindness. Additionally, ILUVIEN helps prevent relapses of recurrent non-infectious uveitis affecting the posterior segment of the eye. The company distributes its products directly and through distributors to various healthcare entities such as physician offices, pharmacies, and hospitals. Alimera also maintains a collaboration with EyePoint Pharmaceuticals US, Inc. focused on developing and marketing insert technology. This technology is designed to deliver corticosteroids to the back of the eye for treating and preventing various human eye diseases, including diabetic macular edema. Founded in 2003, Alimera Sciences is headquartered in Alpharetta, Georgia.
株価
$5.54
最終同期: 2024-09-18
時価総額
$38.76M
変化(1日)
0.00%
変化(1年)
0.00%
US
取引 Alimera Sciences, Inc. (ALIM)

カテゴリー

Alimera Sciences, Inc.(ALIM)の収益
Jun 2024 時点の収益 TTM: $99.68M
Alimera Sciences, Inc. の最新の財務報告によると、現在の収益 (TTM) は $99.68M です。2022 年には $54.13M の収益があり、これは 2021 年の $59.03M と比較して 減少 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Alimera Sciences, Inc. の収益履歴(2006 ~ 2026)
各年末の収益
収益 変化
2026 (TTM) $99.68M 23.44%
2023 $80.75M 49.19%
2022 $54.13M -8.30%
2021 $59.03M 16.15%
2020 $50.82M -5.79%
2019 $53.94M 14.85%
2018 $46.97M 30.79%
2017 $35.91M 4.60%
2016 $34.33M 53.01%
2015 $22.44M 166.39%
2014 $8.42M 349.95%
2013 $1.87M 0.00%
2012 0.00 0.00%
2011 0.00 0.00%
2010 0.00 0.00%
2009 0.00 0.00%
2008 0.00 0.00%
2007 0.00 0.00%
2006 0.00 0.00%